“Increasing Demand for High-Yield, Scalable Protein Production Platforms”
- A significant and accelerating trend in the global eukaryotic expression systems market is the increasing reliance on high-efficiency platforms for producing complex recombinant proteins used in therapeutics, diagnostics, and vaccine development
- For instance, Chinese Hamster Ovary (CHO) cells are widely used in biologics manufacturing due to their ability to produce human-like glycosylation patterns. Companies are investing in optimizing these systems to reduce costs and improve yields
- Eukaryotic systems such as yeast and insect cells are being leveraged for their scalability and ability to express proteins with post-translational modifications, crucial for the bioactivity of therapeutic proteins
- Moreover, advancements in gene editing tools and synthetic biology are enabling more precise genetic modifications in host systems such as S. cerevisiae, thereby improving productivity and customization
- Integration of these systems into bioprocess automation workflows is driving greater reproducibility and efficiency, making them increasingly attractive for large-scale commercial use
- As regulatory bodies increasingly favor biologics and biosimilars, demand for robust, compliant, and cost-effective expression systems is surging across both established markets and emerging economies. This is paving the way for expanded adoption of eukaryotic expression platforms in drug discovery and biomanufacturing pipelines
